These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
286 related items for PubMed ID: 8381275
1. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Masuoka H, Ito M, Sugioka M, Kozeki H, Konishi T, Tanaka T, Nakano T. Biochem Biophys Res Commun; 1993 Jan 29; 190(2):412-7. PubMed ID: 8381275 [Abstract] [Full Text] [Related]
2. Differential modulation of cytokine production by drugs: implications for therapy in heart failure. Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S. J Mol Cell Cardiol; 1996 Dec 29; 28(12):2491-9. PubMed ID: 9004165 [Abstract] [Full Text] [Related]
3. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Ko WC, Shih CM, Lai YH, Chen JH, Huang HL. Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679 [Abstract] [Full Text] [Related]
4. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Torphy TJ, Zhou HL, Burman M, Huang LB. Mol Pharmacol; 1991 Mar 15; 39(3):376-84. PubMed ID: 1848659 [Abstract] [Full Text] [Related]
5. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Torphy TJ, Cieslinski LB. Mol Pharmacol; 1990 Feb 15; 37(2):206-14. PubMed ID: 2154670 [Abstract] [Full Text] [Related]
6. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. de Cheffoy de Courcelles D, de Loore K, Freyne E, Janssen PA. J Pharmacol Exp Ther; 1992 Oct 15; 263(1):6-14. PubMed ID: 1328613 [Abstract] [Full Text] [Related]
7. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Eckly AE, Lugnier C. Br J Pharmacol; 1994 Oct 15; 113(2):445-50. PubMed ID: 7834194 [Abstract] [Full Text] [Related]
8. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Mol Pharmacol; 1986 May 15; 29(5):506-14. PubMed ID: 3010079 [Abstract] [Full Text] [Related]
16. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Biochem Pharmacol; 1986 Mar 01; 35(5):787-800. PubMed ID: 3006691 [Abstract] [Full Text] [Related]
17. Changes in phosphodiesterase activity in the developing rat submandibular gland. Tanaka S, Shimooka S, Shimomura H. Arch Oral Biol; 2002 Aug 01; 47(8):567-76. PubMed ID: 12221013 [Abstract] [Full Text] [Related]
18. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Sugioka M, Ito M, Masuoka H, Ichikawa K, Konishi T, Tanaka T, Nakano T. Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep 01; 350(3):284-93. PubMed ID: 7824045 [Abstract] [Full Text] [Related]
19. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism. Ahn HS, Eardley D, Watkins R, Prioli N. Biochem Pharmacol; 1986 Apr 01; 35(7):1113-21. PubMed ID: 2421728 [Abstract] [Full Text] [Related]